Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.12)
# 444
Out of 4,869 analysts
226
Total ratings
43.26%
Success rate
15.44%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $4.63 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $22.71 | +23.29% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $107.51 | +39.52% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $100.69 | +51.95% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $12.31 | +13.73% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $27.31 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $14.46 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $11.59 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $31.89 | +81.88% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $29.09 | +47.82% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $32.43 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.72 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $126.55 | +22.48% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.15 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $13.89 | +151.98% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.52 | +187.93% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.78 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.26 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.05 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.48 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $22.48 | +51.25% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $30.16 | +65.78% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $4.79 | +4.38% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.58 | +589.66% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.26 | +217.46% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $32.06 | +80.91% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $110 | $1.03 | +10,579.61% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $4.28 | +1,769.16% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.24 | +141.94% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $9.09 | +21.01% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $7.85 | +52.87% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.41 | +2,520.90% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.09 | +856.94% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $15.55 | +1,186.50% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.31 | +1,188.66% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $1.99 | +1,106.03% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.96 | +7,246.94% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.51 | +164.90% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $52.81 | -26.15% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $71.38 | -78.99% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.46 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $7.03 | +2,460.46% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.63
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $22.71
Upside: +23.29%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $107.51
Upside: +39.52%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $100.69
Upside: +51.95%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $12.31
Upside: +13.73%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $27.31
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.46
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.59
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $31.89
Upside: +81.88%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $29.09
Upside: +47.82%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.43
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.72
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $126.55
Upside: +22.48%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.15
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $13.89
Upside: +151.98%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.52
Upside: +187.93%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.78
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.26
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.05
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.48
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $22.48
Upside: +51.25%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $30.16
Upside: +65.78%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $4.79
Upside: +4.38%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.58
Upside: +589.66%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.26
Upside: +217.46%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $32.06
Upside: +80.91%
Aug 22, 2023
Reiterates: Overweight
Price Target: $110
Current: $1.03
Upside: +10,579.61%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $4.28
Upside: +1,769.16%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.24
Upside: +141.94%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $9.09
Upside: +21.01%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.85
Upside: +52.87%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.41
Upside: +2,520.90%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.09
Upside: +856.94%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $15.55
Upside: +1,186.50%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.31
Upside: +1,188.66%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $1.99
Upside: +1,106.03%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.96
Upside: +7,246.94%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.51
Upside: +164.90%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $52.81
Upside: -26.15%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $71.38
Upside: -78.99%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.46
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $7.03
Upside: +2,460.46%